Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters
Jansy P. Sarathy, Véronique Dartois
Clinical Microbiology Reviews (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Véronique Dartois, Eric J. Rubin
Nature Reviews Microbiology (2022) Vol. 20, Iss. 11, pp. 685-701
Open Access | Times Cited: 329
Immune evasion and provocation by Mycobacterium tuberculosis
Pallavi Chandra, Steven J. Grigsby, Jennifer A. Philips
Nature Reviews Microbiology (2022) Vol. 20, Iss. 12, pp. 750-766
Open Access | Times Cited: 322
A mycobacterial effector promotes ferroptosis-dependent pathogenicity and dissemination
Lihua Qiang, Yong Zhang, Zehui Lei, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 62
How macrophage heterogeneity affects tuberculosis disease and therapy
David G. Russell, Nelson V. Simwela, Joshua T. Mattila, et al.
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 4
In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses
Mark R. Cronan
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 65
A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum
Jansy P. Sarathy, Min Xie, R. Mark Jones, et al.
mBio (2023) Vol. 14, Iss. 2
Open Access | Times Cited: 23
Host stress drives tolerance and persistence: The bane of anti-microbial therapeutics
Sophie Hélaine, Brian P. Conlon, Kimberly M. Davis, et al.
Cell Host & Microbe (2024) Vol. 32, Iss. 6, pp. 852-862
Open Access | Times Cited: 13
The immunometabolic topography of tuberculosis granulomas governs cellular organization and bacterial control
Erin McCaffrey, Alea Delmastro, Isobel Fitzhugh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 1
A Physiologically Relevant In Vitro Model of Nonreplicating Persistent Mycobacterium tuberculosis in Caseum
Min Xie, Paulina Osiecki, Sergio D. Rodríguez, et al.
Current Protocols (2025) Vol. 5, Iss. 3
Open Access | Times Cited: 1
Triacylglycerols: Fuelling the Hibernating Mycobacterium tuberculosis
Rahul Kumar Maurya, Suman Bharti, Manju Yasoda Krishnan
Frontiers in Cellular and Infection Microbiology (2019) Vol. 8
Open Access | Times Cited: 56
Antibiotic tolerance
Lars F. Westblade, Jeff Errington, Tobias Dörr
PLoS Pathogens (2020) Vol. 16, Iss. 10, pp. e1008892-e1008892
Open Access | Times Cited: 56
Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis
Jonah Larkins‐Ford, Talia Greenstein, Nhi Van, et al.
Cell Systems (2021) Vol. 12, Iss. 11, pp. 1046-1063.e7
Open Access | Times Cited: 56
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832
Gregory T. Robertson, Michelle E. Ramey, Lisa M. Massoudi, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 11
Open Access | Times Cited: 54
Types and functions of heterogeneity in mycobacteria
Eun Seon Chung, William Johnson, Bree B. Aldridge
Nature Reviews Microbiology (2022) Vol. 20, Iss. 9, pp. 529-541
Open Access | Times Cited: 38
Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy
Richard C. Lavin, Shumin Tan
PLoS Pathogens (2022) Vol. 18, Iss. 3, pp. e1010459-e1010459
Open Access | Times Cited: 32
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment
Eric L. Nuermberger, María Santos Martínez, Olalla Sanz, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 6
Open Access | Times Cited: 31
IFN-γ-independent control of M. tuberculosis requires CD4 T cell-derived GM-CSF and activation of HIF-1α
Erik Van Dis, Douglas Fox, Huntly M. Morrison, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 7, pp. e1010721-e1010721
Open Access | Times Cited: 30
Novel targets and inhibitors of the Mycobacterium tuberculosis cytochrome bd oxidase to foster anti-tuberculosis drug discovery
Amaravadhi Harikishore, Vikneswaran Mathiyazakan, Kévin Pethe, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 8, pp. 917-927
Open Access | Times Cited: 20
Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses
Nicholas D. Walter, Jacqueline P. Ernest, Christian Dide-Agossou, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 9
Open Access | Times Cited: 19
Reframing antimicrobial resistance as a continuous spectrum of manifestations
Sarah Schrader, Hélène Botella, Julien Vaubourgeix
Current Opinion in Microbiology (2023) Vol. 72, pp. 102259-102259
Open Access | Times Cited: 17
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis
Si‐Yang Li, Sandeep Tyagi, Heena Soni, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 4
Open Access | Times Cited: 7
Tuberculosis treatment-shortening
Vinayak Singh
Drug Discovery Today (2024) Vol. 29, Iss. 5, pp. 103955-103955
Open Access | Times Cited: 7
Pathogenesis of Human Immunodeficiency Virus-Mycobacterium tuberculosis Co-Infection
Kevin Wong, James Nguyen, Lillie Blair, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 11, pp. 3575-3575
Open Access | Times Cited: 40
Neutrophil Dynamics Affect Mycobacterium tuberculosis Granuloma Outcomes and Dissemination
Caitlin Hult, Joshua T. Mattila, Hannah P. Gideon, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 35
Advances in the design of combination therapies for the treatment of tuberculosis
Jonah Larkins‐Ford, Bree B. Aldridge
Expert Opinion on Drug Discovery (2022) Vol. 18, Iss. 1, pp. 83-97
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top